These are the excellent presentations from the Children with Cancer UK sponsored childhood cancer session organised by Professor Denis Henshaw for the 8th Princess Chulabhorn International Scientific Congress held in Thailand in November 2016.

Precision Medicine in Childhood and TYA Cancer Hype or Hope?

Progress in molecular and cellular bio technologies has heralded the advent of an era of precision cancer medicine in which real time use of molecular genetics can be harnessed to deliver more effective, less toxic therapies. The Trustees of CwC UK UK are keen to make a major contribution to funding this technology in the UK. Our aim in this meeting is to better understand the progress and ongoing challenges in this field and how we might meet these challenges to achieve our goal of ensuring that precision medicine and, where available, targeted therapy is available to all children and young adult in the UK at diagnosis. The meeting is structured as follows:

Day 1 - 18th September 2017

1030 - 1230 - Session 1 - Introduction - Annual Progress Update from Children with Cancer UK
This session will provide continuity with our 2016 meeting. International experts will provide concise updates of progress in immunotherapy of leukaemia, drug delivery in brain tumours and the ongoing evolution of our understanding of factors involved in causation of childhood cancer. The session will close with discussion of CwC UK sponsored research funding opportunities for 2018 which will lead us in to the main meeting.

1230-1330 Lunch

1330-1530 - Session 2 - Improving accuracy of diagnosis and risk stratification
Sub- classification of diseases in order to refine diagnosis and more accurately stratify prognosis and guide therapy has been a feature of paediatric oncology for over 50 years. Precision medicine technologies have further strengthened this effort, in some cases re - defining entire disease types and in others allowing a more accurate diagnosis with implication for therapy and causation. In addition the enhanced sensitivity provided by modern sequencing technologies means that liquid biopsy of circulating DNA rather than biopsy of bulk tumour is now a reality. These developments will be illustrated by four plenary presentations, covering medulloblastoma, acute myeloid leukaemia, rare haematological malignancies and rare solid tumours.

1530-1600 Comfort break

1600-1730 - Session 3 - Integrating Genomics and Disease Modelling to Develop Targeted Therapies
Pre clinical science holds the key to successfully harnessing the potential power of precision medicine. In this session three leading experts will illustrate approaches to discovery of new targets in acute leukaemia, brain tumours and neuroblastoma. They will focus on the importance of the development of preclinical models that replicate the changes seen in specific tumours as well as the need to study both diagnostic and relapse material. Each speaker will also show how an understanding the role of germline changes is beginning to allow us to understand the molecular steps involved in the development of cancer

1730-1845 - Session 4 - Poster Session with Refreshments to finish with Presentation of Prizes at 1830
A call for abstracts of original research, for presentation at the meeting focussing, on the use of precision medicine in diagnostics and targeted therapy will be issued by CwC UK in March 2017. The conference scientific committee will select three leading abstracts for oral presentation All other accepted abstracts will be presented as posters in this session which will be followed by the conference dinner

1900 Children with Cancer UK Conference Dinner

Day 2 - 19th September 2017

0845-1030 Session 5 - Current & Future Clinical Trials of Targeted Therapy
Proof of the value of precision medicine can only come from well-designed clinical trials. In this session four experts will discuss the challenges of moving from the preclinical to clinical application, the role of pharmacology and the challenges in designing trials of medicines targeted at genomic changes that may often occur at low frequency and in multiple tumour types. The final speaker in this session will discuss the health economics of focussing on the need to balance funding constraints with an absolute commitment to improve survival and quality of survival

1530-1600 Refreshment break

1100 - 1200 - Session 6 - Oral Free Communications (Submitted Poster Abstracts)
A call for Poster abstracts of original research focussing on the use of precision medicine in diagnostics and targeted therapy will be issued by CwC UK in March 2017. The conference scientific committee will select three leading abstracts for oral presentation. All other accepted abstracts will be presented as posters in session 4

1200 - 1300 - Session 7 - Presentation of UK Initiatives in PM
This final session of the main meeting will discuss two important precision medicine initiatives funded in significant part by CwC UK – namely the SMPaeds and INSTINCT projects. Speakers will outline the aims and scope of these projects and how they can be accessed by individual clinical centres

1300-1400 Lunch

1400 - 1600 - Session 8 - Workshop Integrating genomics into studies of toxicity and quality of survival
Inevitably much of the focus of the value of precision medicine has been on the development of new targeted therapies. Nevertheless, it is important to recognise that many children and young adults will continue to receive standard therapy with its attendant short and long term side effects. This workshop aims to understand how the use of genetic technologies to predict both short and long term toxicities might be incorporated into clinical trials.

1600 Conference ends

51 Great Ormond Street, London, WC1N 3JQ
Tel: 020 7404 0808,     Registered Charity Number: 298405
Inaugurated by Diana, Princess of Wales